Rapid Micro Biosystems (RPID) FCF Margin (2020 - 2026)
Rapid Micro Biosystems (RPID) reported FCF Margin of 188.34% for Q1 2026, down 5810.0% on a YoY basis from 3.3% in Q1 2025, and down 749.94% sequentially from 22.16% in Q4 2025.
Rapid Micro Biosystems (RPID) FCF Margin (2020 - 2026) Analysis & Trends
Rapid Micro Biosystems (RPID) has 7 years of FCF Margin data on file, last reported at 188.34% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 5810.0% year-over-year to 188.34%; the trailing twelve-month figure through Mar 2026 stood at 106.91% (up 2394.0% YoY), and the FY2025 full-year result was 92.52%, up 6975.0% from the prior year.
- FCF Margin eased to 188.34% in Q1 2026, from 22.16% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 22.16% in Q4 2025 to a low of 460.43% in Q1 2022.
- A 5-year average of 203.56% and a median of 146.57% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin sank 22994 bps in 2022 and surged 27827 bps in 2023, its largest moves.
- Tracing RPID's FCF Margin over 5 years: stood at 126.82% in 2022, then dropped by 16 bps to 146.57% in 2023, then grew by 7 bps to 136.85% in 2024, then surged by 84 bps to 22.16% in 2025, then sank by 750 bps to 188.34% in 2026.
- Business Quant data shows RPID's FCF Margin at 188.34% in Q1 2026, 22.16% in Q4 2025, and 124.19% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -1.28% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 37.67% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.68% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.18% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Rapid Micro Biosystems | 90.41 Mn | 80.98 Mn | 371,000.00 | -188.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -188.34% |
| Dec 31, 2025 | -22.16% |
| Sep 30, 2025 | -124.19% |
| Jun 30, 2025 | -130.21% |
| Mar 31, 2025 | -130.24% |
| Dec 31, 2024 | -136.85% |
| Sep 30, 2024 | -113.48% |
| Jun 30, 2024 | -144.05% |
| Mar 31, 2024 | -287.11% |
| Dec 31, 2023 | -146.57% |
| Sep 30, 2023 | -157.56% |
| Jun 30, 2023 | -173.15% |
| Mar 31, 2023 | -346.47% |
| Dec 31, 2022 | -126.82% |
| Sep 30, 2022 | -435.83% |
| Jun 30, 2022 | -337.12% |
| Mar 31, 2022 | -460.43% |
| Dec 31, 2021 | -268.57% |
| Sep 30, 2021 | -290.71% |
| Jun 30, 2021 | -185.40% |